Overview

An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola

Status:
Withdrawn

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine how safe and tolerable Brincidofovir (BCV) is when given for post exposure prophylaxis of Ebola virus disease.

Phase:

Phase 2

Details

Lead Sponsor:

Chimerix

Collaborator:

Food and Drug Administration (FDA)

Treatments:

Brincidofovir